• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.肝细胞癌诊断时的表现差异:一项美国安全网合作研究。
Ann Surg Oncol. 2021 Apr;28(4):1929-1936. doi: 10.1245/s10434-020-09156-4. Epub 2020 Sep 25.
2
Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma.种族和民族差异对肝细胞癌的表现和结果的影响。
Clin Gastroenterol Hepatol. 2019 Feb;17(3):551-559.e1. doi: 10.1016/j.cgh.2018.05.039. Epub 2018 May 31.
3
Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment.医疗补助计划参保者及未参保的肝细胞癌患者肿瘤分期更高,接受治疗的可能性更低。
J Clin Gastroenterol. 2018 May/Jun;52(5):437-443. doi: 10.1097/MCG.0000000000000859.
4
Comparing barriers to early stage diagnosis of hepatocellular carcinoma between safety net hospitals and academic medical centers: An analysis from the United States Safety-Net Collaborative.比较安全网医院和学术医疗中心在肝细胞癌早期诊断方面的障碍:来自美国安全网合作组织的分析。
J Surg Oncol. 2024 Sep;130(3):493-503. doi: 10.1002/jso.27787. Epub 2024 Aug 1.
5
Dissecting disease, race, ethnicity, and socioeconomic factors for hepatocellular carcinoma: An analysis from the United States Safety Net Collaborative.剖析肝癌的疾病、种族、民族和社会经济因素:来自美国安全网协作的分析。
Surg Oncol. 2020 Dec;35:120-125. doi: 10.1016/j.suronc.2020.08.009. Epub 2020 Aug 23.
6
Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies.肝细胞癌诊断分期中种族/族裔特异性差异及其对根治性治疗接受情况的影响
J Clin Gastroenterol. 2016 May-Jun;50(5):423-30. doi: 10.1097/MCG.0000000000000448.
7
Opportunities to Improve Care of Hepatocellular Carcinoma in Vulnerable Patient Populations.改善弱势群体肝细胞癌护理的机会。
J Am Coll Surg. 2017 Apr;224(4):697-704. doi: 10.1016/j.jamcollsurg.2016.12.023. Epub 2017 Jan 6.
8
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States.美国晚期 HCC 免疫治疗早期治疗中的种族和民族差异。
Hepatology. 2022 Dec;76(6):1649-1659. doi: 10.1002/hep.32527. Epub 2022 Apr 27.
9
Impact of Primary Care Physician Interaction on Longitudinal Adherence to Screening Mammography Across Different Racial/Ethnic Groups.基层医疗保健医生互动对不同种族/族裔群体纵向筛查乳房 X 光照片依从性的影响。
J Am Coll Radiol. 2019 Jul;16(7):908-914. doi: 10.1016/j.jacr.2018.12.020. Epub 2019 Feb 6.
10
Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.早期肝细胞癌患者在获得医疗服务和生存方面的种族/族裔差异。
Arch Surg. 2010 Dec;145(12):1158-63. doi: 10.1001/archsurg.2010.272.

引用本文的文献

1
Geographic diversity of human liver cancers mirrors global social inequalities.人类肝癌的地理多样性反映了全球社会不平等现象。
Front Oncol. 2025 May 16;15:1565692. doi: 10.3389/fonc.2025.1565692. eCollection 2025.
2
Registry versus claims-based index dates for studies of cancer diagnosis in administrative data.行政数据中癌症诊断研究的登记日期与基于索赔的索引日期对比
Cancer Causes Control. 2025 May;36(5):539-550. doi: 10.1007/s10552-024-01953-6. Epub 2025 Jan 9.
3
Ethnic disparities in the epidemiology, treatment, and outcome of patients with hepatocellular carcinoma in the United States.美国肝细胞癌患者在流行病学、治疗及预后方面的种族差异。
Hepatoma Res. 2023;9. doi: 10.20517/2394-5079.2023.10. Epub 2023 May 18.
4
Disparities in the first-ever diagnosed liver cancers between the emergency department and outpatient department in Taiwan: a population-based study.台湾地区急诊部和门诊部首次诊断出的肝癌之间的差异:一项基于人群的研究。
BMC Public Health. 2023 Feb 8;23(1):283. doi: 10.1186/s12889-023-15218-5.
5
An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma.肝细胞癌筛查、治疗及预后的个体和背景水平差异分析
J Hepatocell Carcinoma. 2021 Sep 28;8:1209-1219. doi: 10.2147/JHC.S284430. eCollection 2021.
6
Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis.新辅助化疗治疗胃腺癌期间的损耗与生存降低相关:美国医疗保障安全网协作分析。
J Surg Oncol. 2021 Dec;124(8):1317-1328. doi: 10.1002/jso.26638. Epub 2021 Aug 11.
7
Surgical oncology operative experience at a high-volume safety-net hospital during the COVID-19 pandemic.在 COVID-19 大流行期间,高容量安全网医院的外科肿瘤手术经验。
J Surg Oncol. 2021 Dec;124(7):983-988. doi: 10.1002/jso.26616. Epub 2021 Jul 22.
8
Overcoming Disparities in Cancer: A Need for Meaningful Reform for Hispanic and Latino Cancer Survivors.克服癌症差异:西班牙裔和拉丁裔癌症幸存者需要有意义的改革。
Oncologist. 2021 Jun;26(6):443-452. doi: 10.1002/onco.13729. Epub 2021 Mar 10.
9
ASO Author Reflections: Access to Care and Screening Inequities for Patients At Risk for Hepatocellular Carcinoma.美国骨科学会作者反思:肝细胞癌高危患者的医疗服务可及性与筛查不平等问题
Ann Surg Oncol. 2021 Apr;28(4):1937-1938. doi: 10.1245/s10434-020-09172-4. Epub 2020 Sep 24.

本文引用的文献

1
Continuing Challenges in Rural Health in the United States.美国农村卫生领域持续存在的挑战。
J Environ Health Sci. 2019;5(2):90-92. Epub 2019 Dec 16.
2
The Gastroenterologist's Guide to Preventive Management of Compensated Cirrhosis.《胃肠病学家对代偿期肝硬化预防性管理指南》
Gastroenterol Hepatol (N Y). 2019 Aug;15(8):423-430.
3
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?丙型肝炎病毒时代的肝细胞癌:我们是否应该改变范式?
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940. doi: 10.3748/wjg.v25.i29.3929.
4
Hepatocellular carcinoma surveillance: An evidence-based approach.肝细胞癌监测:基于证据的方法。
World J Gastroenterol. 2019 Apr 7;25(13):1550-1559. doi: 10.3748/wjg.v25.i13.1550.
5
Disease Burden of Hepatocellular Carcinoma: A Global Perspective.肝癌疾病负担:全球视角。
Dig Dis Sci. 2019 Apr;64(4):910-917. doi: 10.1007/s10620-019-05537-2.
6
Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes.种族和地域差异对肝细胞癌结局的影响。
Am J Prev Med. 2018 Nov;55(5 Suppl 1):S40-S48. doi: 10.1016/j.amepre.2018.05.030.
7
Urban-Rural Disparity in Cancer Incidence, Mortality, and Survivals in Shanghai, China, During 2002 and 2015.2002年至2015年期间中国上海城乡地区癌症发病率、死亡率及生存率的差异
Front Oncol. 2018 Dec 3;8:579. doi: 10.3389/fonc.2018.00579. eCollection 2018.
8
Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population.在服务不足人群中丙型肝炎治愈后的肝病监测实践
Hepatol Commun. 2018 Sep 24;2(10):1274-1283. doi: 10.1002/hep4.1246. eCollection 2018 Oct.
9
Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention.加利福尼亚州按种族/族裔和地理区域划分的肝细胞癌发病率差异:对预防的影响。
Cancer. 2018 Sep 1;124(17):3551-3559. doi: 10.1002/cncr.31598. Epub 2018 Aug 16.
10
Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance.初级保健提供者的实践模式及肝癌监测的障碍。
Clin Gastroenterol Hepatol. 2019 Mar;17(4):766-773. doi: 10.1016/j.cgh.2018.07.029. Epub 2018 Jul 26.

肝细胞癌诊断时的表现差异:一项美国安全网合作研究。

Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study.

作者信息

Kronenfeld Joshua P, Ryon Emily L, Goldberg David, Lee Rachel M, Yopp Adam, Wang Annie, Lee Ann Y, Luu Sommer, Hsu Cary, Silberfein Eric, Russell Maria C, Livingstone Alan S, Merchant Nipun B, Goel Neha

机构信息

Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.

Division of Digestive Health and Liver Disease, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

Ann Surg Oncol. 2021 Apr;28(4):1929-1936. doi: 10.1245/s10434-020-09156-4. Epub 2020 Sep 25.

DOI:10.1245/s10434-020-09156-4
PMID:32975686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8099037/
Abstract

BACKGROUND

While hepatocellular carcinoma (HCC) is ideally diagnosed outpatient by screening at-risk patients, many are diagnosed in Emergency Departments (ED) due to undiagnosed liver disease and/or limited access-to-healthcare. This study aims to identify sociodemographic/clinical factors associated with being diagnosed with HCC in the ED to identify patients who may benefit from improved access-to-care.

METHODS

HCC patients diagnosed between 2012 and 2014 in the ED or an outpatient setting [Primary Care Physician (PCP) or hepatologist] were identified from the US Safety-Net Collaborative database and underwent retrospective chart-review. Multivariable regression identified predictors for an ED diagnosis.

RESULTS

Among 1620 patients, median age was 60, 68% were diagnosed outpatient, and 32% were diagnosed in the ED. ED patients were more likely male, Black/Hispanic, uninsured, and presented with more decompensated liver disease, aggressive features, and advanced clinical stage. On multivariable regression, controlling for age, gender, race/ethnicity, poverty, insurance, and PCP/navigator access, predictors for ED diagnosis were male (odds ratio [OR] 1.6, 95% confidence interval [CI]: 1.1-2.2, p = 0.010), black (OR 1.7, 95% CI: 1.2-2.3, p = 0.002), Hispanic (OR 1.6, 95% CI: 1.1-2.6, p = 0.029), > 25% below poverty line (OR 1.4, 95% CI: 1.1-1.9, p = 0.019), uninsured (OR 3.9, 95% CI: 2.4-6.1, p < 0.001), and lack of PCP (OR 2.3, 95% CI: 1.5-3.6, p < 0.001) or navigator (OR 1.8, 95% CI: 1.3-2.5, p = 0.001).

CONCLUSIONS

The sociodemographic/clinical profile of patients diagnosed with HCC in EDs differs significantly from those diagnosed outpatient. ED patients were more likely racial/ethnic minorities, uninsured, and had limited access to healthcare. This study highlights the importance of improved access-to-care in already vulnerable populations.

摘要

背景

虽然肝细胞癌(HCC)理想情况下是通过对高危患者进行筛查在门诊诊断出来的,但由于肝病未被诊断和/或获得医疗保健的机会有限,许多患者是在急诊科(ED)被诊断出来的。本研究旨在确定与在急诊科被诊断为HCC相关的社会人口统计学/临床因素,以识别可能从改善医疗服务可及性中受益的患者。

方法

从美国安全网协作数据库中识别出2012年至2014年期间在急诊科或门诊环境(初级保健医生[PCP]或肝病专家)被诊断为HCC的患者,并进行回顾性病历审查。多变量回归确定了急诊科诊断的预测因素。

结果

在1620名患者中,中位年龄为60岁,68%在门诊被诊断,32%在急诊科被诊断。急诊科患者更可能是男性、黑人/西班牙裔、未参保,并且表现出更多失代偿性肝病、侵袭性特征和晚期临床分期。在多变量回归中,在控制年龄、性别、种族/民族、贫困、保险以及PCP/导航员可及性后,急诊科诊断的预测因素为男性(优势比[OR]1.6,95%置信区间[CI]:1.1 - 2.2,p = 0.010)、黑人(OR 1.7,95% CI:1.2 - 2.3,p = 0.002)、西班牙裔(OR 1.6,95% CI:1.1 - 2.6,p = 0.029)、贫困线以下超过25%(OR 1.4,95% CI:1.1 - 1.9,p = 0.019)、未参保(OR 3.9,95% CI:2.4 - 6.1,p < 0.001),以及缺乏PCP(OR 2.3,95% CI:1.5 - 3.6,p < 0.001)或导航员(OR 1.8,95% CI:1.3 - 2.5,p = 0.001)。

结论

在急诊科被诊断为HCC的患者的社会人口统计学/临床特征与门诊诊断的患者有显著差异。急诊科患者更可能是种族/民族少数群体、未参保,并且获得医疗保健的机会有限。本研究强调了在本已脆弱的人群中改善医疗服务可及性的重要性。